Table 2.

In vivo antitumor effects of oridonin (ORI) solution, ORI-loaded atactic poly(d,l-lactic acid) nanoparticles (ORI-PLA-NPs), and ORI-PLA-NPs further modified by surface cross-linking with the peptide Arg-Gly-Asp (ORI-PLA-RGD-NPs)

Group	Tumor volume (cm3)	Tumor weight (g)
Normal saline	1.05 ± 0.32	4.50 ± 0.84
ORI solution	0.71 ± 0.27*,c	3.27 ± 0.44**,b,c
ORI-PLA-NP	0.50 ± 0.11**	1.95 ± 0.40**,a,c
ORI-PLA-RGD-NP	0.24 ± 0.04**,a	1.01 ± 0.23**,a,b

Notes: Mean tumor volumes and weights are from groups of six mice injected once daily for 10 days. Mice were sacrificed 24 hours after the final dose.

^*P < 0.05 and

^**P < 0.01 compared with normal saline group;

^aP < 0.01 compared with ORI solution group;

^bP < 0.01 compared with ORI-PLA-NP group;

^cP < 0.01 compared with ORI-PLA-RGD-NP group.